Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Payer

- PMLiVE

US Senator sets sights on medicine pricing

Intends to stop rises in drug prices for US public

- PMLiVE

Creating stability with medicines framework

The deals secure stability for both industry and governments

- PMLiVE

Making savings from European drugs budgets

National programmes of cuts are the order of the day

Friend or foe?

Payer relationship might have unintended consequences

- PMLiVE

Overcoming quantitative pricing limitations

Choosing an accurate price for a product without a therapeutic equivalent can feel like a lead in the dark

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

- PMLiVE

Merck Serono joins CAR-T race with $941m Intrexon deal

Will collaborate on therapy to recognise and attack antigens on tumour cells

- PMLiVE

WHO: Medicine costs ‘too high’ for European governments

New report shows transparency and co-operation needed to help reduce drug prices

How the focus on patient outcomes has allowed FMCG to enter into healthcare market

Associate Consultant Mette Drabæk talks about how the increase in ability to measure real-world patient outcomes has strengthened the position of the payer when negotiating reimbursement contracts with pharma companies.

Blue Latitude Health

- PMLiVE

US seeking price cuts for Medicare drugs

White House proposes allowing Medicare Part D to haggle with pharma companies for discounts

The seven letter debate that is Sovaldi

Reimbursement of high cost hepatitis C drugs raise difficult issues

- PMLiVE

Gilead taken to task over Sovaldi pricing

US politicians question high cost of new hepatitis C drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links